Turn Therapeutics Inc. · NASDAQ:TTRX
Turn Therapeutics — Investor Presentation (September 2025)
24 slides from Turn Therapeutics's investor presentation, September 2025
Slide 1: Investor Presentation
TURN THERAPEUTICS Investor Presentation
Slide 2: Disclaimer
Disclaimer This presentation relating to Global Health Solutions, Inc., dba Turn Therapeutics (the “Company”), has been This presentation includes market and industry data and forecasts that the Company has derived from These forward-looking statements, which are subject to risks, uncertainties and
Slide 3: Business & Development Plan, Financials, Appendix
Business & Development Plan Financials Appendix 3
Slide 4: Necessity: The Mother of All Invention
Necessity: The Mother of All Invention Key Milestones November 2016 August 2017 October 2019 December 2022 July 2025 Founder Bradley Burnam achieves FDA clearance for GX-03/Hexagen for use in FDA clearance for GX-03/Hexagen for use in Series B: $5.1mm to support preclinical License and development p
Slide 5: Management & Board
Management & Board Key Management Zuraiz Chaudhary, CPA Dr. Neil Ghodadra, MD Muhammad Zubair, CPA Angbeen Chaudary David Swoish Conoon Kim Bradley Burnam Chief of Staff Operations Digital Technology Chief Executive Officer, Chief Accounting Officer, VP Chief Medical Officer Controller Finance 9+ Ye
Slide 6: Business Overview
Business Overview By the Numbers 15 3+ 200k+ $69M+ Issued Drugs in Patients License Patents Pipeline Treated Deal(1) Our Key Pillars Medical device products are To advance multiple clinical stage Out-licensing model is expected Visionary founder, a well expected to create financial assets through Ph
Slide 7: PermaFusion: A Revolutionary Delivery Platform
PermaFusion : A Revolutionary Delivery Platform 1.3 Micron Active ingredient nanodroplets suspended Patented Multi-Step within petrolatum matrix API in Mixing Process Petro / Oil Liquid w/out Carrier Solvent Emulsifier A potentially transformative delivery platform enabling stable, emulsifier-free d
Slide 8: Product Portfolio
Product Portfolio Intranasal Vaccine Onychomycosis Positive partnership results Look to initiate Phase 3 in 2026 Permafusion Based Assets XEAL Moderate-Severe FDA cleared, partnership pending Eczema Phase 2 commenced July 2025 FLEX AM Exclusive license with Mimedix “Putting together Turn’s intellect
Slide 9: Hexagen/GX-03: Flagship Formula
Hexagen/GX-03: Flagship Formula 3 FDA medical device clearances for GX-03/Hexagen in advanced wound and dermatitis management 200k Documented use cases on patients suffering from conditions ranging from advanced, critically colonized wounds to dermatitis Skin / Nail Surface Non-Cytotoxic FDA clearan
Slide 10: Pipeline Defined By Market Opportunities
Pipeline Defined By Market Opportunities Unmet Need Meets High-Value Markets Moderate to Severe Onychomycosis (Nail Thermostable Eczema Fungus)(1) Intranasal Vaccine Platform 6.6 $6+ 40.3% $3.8 +150 25% Billion American Share of Global Billion Million Market Uplift Million Total Market Patients(1) T
Slide 11: Evidence Backed Clinical Trials
Moderate to Severe Eczema Examples Subject – Before 70%(1) 16.5mn(2) and After Lesions associated with Current treatments for Evidence Backed Clinical Trials Expanding Hexagen’s moderate to severe moderate to severe indications to treat eczema are colonized eczema are highly eczema facilitates acces
Slide 12: Cytokine Studies Demonstrate Strong Inhibition
Cytokine Studies Demonstrate Strong Inhibition Pre-treatment model to assess blockade potential during induction 90%(1) IL-31 levels, IL-36α is a key of eczema patients exhibit considered to play a cytokine driving a high levels of S. aureus on inflamed skin. significant role in the spectrum of S. a
Slide 13: A Novel Approach to Polymicrobial Nail Infection
A Novel Approach to Polymicrobial Nail Infection R. Daniel Davis, DPM Past President: American Podiatric Medical Association Intro The care and treatment of patients with dystrophic nails continues to be a challenging, expensive, and at times a potentially patient-harming endeavor for today’s physic
Slide 14: Onychomycosis (Nail Fungus)
Onychomycosis (Nail Fungus) Currently approved topical onychomycosis products have failed to penetrate the nail and eliminate fungal pathogens per 10% Of the General Population(2) 6.5-17.8% 70-85% established model(1) Percent of topical Hexagen reported efficacy Establishment of a Novel Model of Ony
Slide 15: Thermostable Intranasal Vaccine Development Partnership
Thermostable Intranasal Vaccine Development Partnership An international non-profit organization’s rVSV-MARV successfully survived 14 days at ambient temperature and 28 days Cold-Chain Stability refrigerated (4°C) with 100% recovery to 10^-7 dilution. Proof that delivery platform can maintain live v
Slide 16: Why Us, Why Now?
Why Us, Why Now? Data Supporting Key Cytokine Inhibition in Eczema and Other Conditions • Recently conducted study demonstrated significant reduction of key cytokines IL-31, IL-36α and IL-36 γ • IGA scores indicate possible elimination of eczema with topical treatment in mice after 3-day pre-treatme
Slide 17: Business & Development Plan, Financials, Appendix
Business & Development Plan Financials Appendix 1 7
Slide 18: Financial Highlights
Financial Highlights Average Monthly Cash Burn(1) vs Peer Average ($000’s) Total money raised since inception through $50.2 $18M 2Q25(1) $9,000 $8,525 $8,000 $7,000 $6,705 $6,000 $15M Cash burned since inception (10 years) (1) $5,000 $4,000 $3,000 $2,924 $18-20M Expected R&D spend to complete Phase
Slide 19: Business & Development Plan, Financials, Appendix
Business & Development Plan Financials Appendix 1 9
Slide 20: Financial Summary
Financial Summary Cash Flow Data ($000’s) Year ended Year ended 6 months ended December 31, December 31, Balance Sheet Data ($000’s) June 30, 2025 ($M) 2024 2023 ($M) ($M) Year ended Year ended 6 months ended December $50.2 31, December 31, Net Cash Used In Operating Activities (798) (1,361) (1,378)
Slide 21: MOA: Inhibition of IL-36 and IL-31
MOA: Inhibition of IL-36 and IL-31 BIOBURDEN LEADS TO IL-36α Activation (1) Eczema affects 20-25% of children and 2-10% percent of adults in industrialized countries. 70% of eczema patients have exceedingly high numbers of S. aureus on their inflamed skin. S. Aureus secretes an inflammatory protein
Slide 22: GX-03 Reduces Disease Severity by 57% In-Vivo
Gx-03 Reduces Disease Severity by 57% In-Vivo Initial Animal Studies Show Significant decrease (1) Utilizing a widely cited in-vivo AD model(1), study showed a dramatic reduction in disease severity vs placebo. At the conclusion of a 7-day disease induction, the mean ISGA score across all groups was
Slide 23: Additional Device Out-License In Active Negotiations
Additional Device Out-License In Active Negotiations FDA Cleared Antimicrobial Oil Emulsion Dressing XEAL Inoculum Average Log Organisms(1) Antimicrobial Oil (cfu/ml) (1) cfu/dressing(1) Reduction(1) Emulsion Dressing MRSA 6.06 X 105 No Growth 5.78 is impregnated 3 Day with Hexagen MRSA 6.06 X 105 N
Slide 24: $85mm Commitment Upon Public Listing
$85mm Commitment Upon Public Listing $85mm Committed over 36 months. “ This investment provides both capital flexibility Global This is a unique share purchase agreement that allows Turn to “put” stock to and firepower. This Emerging private equity fund at a partnership with discount to prevailing m
Turn Therapeutics — Investor Presentation (September 2025) on 6ix